0001209191-19-039262.txt : 20190627
0001209191-19-039262.hdr.sgml : 20190627
20190627162128
ACCESSION NUMBER: 0001209191-19-039262
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20190626
FILED AS OF DATE: 20190627
DATE AS OF CHANGE: 20190627
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Goldman Steven M.
CENTRAL INDEX KEY: 0001568216
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38135
FILM NUMBER: 19925555
MAIL ADDRESS:
STREET 1: C/O DOVA PHARMACEUTICALS, INC.
STREET 2: 240 LEIGH FARM ROAD, SUITE 245
CITY: DURHAM
STATE: NC
ZIP: 27707
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Dova Pharmaceuticals Inc.
CENTRAL INDEX KEY: 0001685071
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 813858961
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 240 LEIGH FARM ROAD
CITY: DURHAM
STATE: NC
ZIP: 27707
BUSINESS PHONE: 919-806-4487
MAIL ADDRESS:
STREET 1: 240 LEIGH FARM ROAD
CITY: DURHAM
STATE: NC
ZIP: 27707
FORMER COMPANY:
FORMER CONFORMED NAME: Dova Pharmaceuticals, Inc.
DATE OF NAME CHANGE: 20160919
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2019-06-26
0
0001685071
Dova Pharmaceuticals Inc.
DOVA
0001568216
Goldman Steven M.
C/O DOVA PHARMACEUTICALS, INC.
240 LEIGH FARM ROAD, SUITE 245
DURHAM
NC
27707
1
0
0
0
Common Stock
2019-06-26
4
M
0
916
7.32
A
143446
D
Common Stock
2019-06-26
4
M
0
834
9.36
A
144280
D
Common Stock
5000
I
By LLC
Stock Option (right to buy)
7.32
2019-06-26
4
M
0
916
0.00
D
2027-05-24
Common Stock
916
10084
D
Stock Option (right to buy)
9.36
2019-06-26
4
M
0
834
0.00
D
2029-04-25
Common Stock
934
8233
D
These shares are held by the Steven M. Goldman Family LLC (the "LLC"), of which the Reporting Person is the Managing Member. The voting and investment decisions of the LLC are made by an independent external asset manager. The Reporting Person disclaims beneficial ownership of the shares held by the LLC except to the extent of his pecuniary interest in the LLC, if any, and the inclusion of these shares on this report shall not be deemed an admission that the Reporting Person beneficially owns the shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or any other purpose.
The option vests over a period of three years as follows: (i) one-third of the total shares subject to the option shall vested on May 25, 2018, and (ii) 1/36th of total shares subject to the option shall vest monthly thereafter over the remaining two years of the vesting period, subject to the Reporting Person's continuous service with the Issuer on each such date. The option allows for early exercise, subject to the Issuer's repurchase option, with respect to any unvested shares of Common Stock.
Vesting monthly over one year from the grant date and in any event will be fully vested on the date of the next annual meeting of our stockholders, subject to continued service as a director though the applicable vesting date.
/s/ Mark Ballantyne, Attorney-in-Fact
2019-06-27